Shigella dysenteriae Type 1 is one of the most fearsome of the Category B Priority agents owing to its high infectivity at low doses, severe disease sequelae, and ability to cause explosive epidemics in naive populations. No prophylactic vaccine or specific therapy exists for prevention of disease caused by this pathogen and therapeutic options are limited against the majority of clinical isolates which are increasingly multiply antibiotic resistant. S. dysenteriae Type 1 is easily spread by tainted food or water and an intentional act of contamination could lead to widespread serious disease and death in a population with no immunity to this organism. Recent clinical trials with attenuated strains of Shigella flexneri have reinforced the safety and efficacy, of live Shigella vaccine candidates and confirmed the attenuating capacity of mutations in the guaBA, set, and sen genes. These data provide a strategy for the rational design of a series of live, attenuated S. dysenteriae vaccine strains based on a combination of these mutations in addition to elimination of shiga toxin activity. In addition, by inserting a constitutive promoter driving expression of the shiga toxin B subunit in these attenuated strains, shiga toxin neutralizing immune responses could be elicited and provide protection not only against S. dysenterae but also against other shiga toxin-producing pathogens. Using our collection of S. flexneri vaccine strains with known clinical outcomes we propose to modify animal and in vitro assays to increase the sensitivity for distinguishing differences between strains at the preclinical level. Refined assays will allow greater predictive power of subsequent clinical performance resulting in accelerated advancement of the most promising candidate strain or strains to clinical trials and production. The live attenuated strains can then be used to express protective antigens or epitopes from other priority pathogens. We will design systems for expression of PA from B. anthracis from stabilized plasmid constructs, chromosomally integrated and in secreted form by fusion to ClyA. Relevance: These studies will result in a series of live attenuated Shigella dysenteriae vaccine candidates for advancement to clinical trials and for use in the development of a multivalent, oral vaccine to protect against multiple priority agent diseases which will help protect citizens from potential biothreats. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI059223-01A2
Application #
7149413
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Van de Verg, Lillian L
Project Start
2006-06-15
Project End
2010-05-31
Budget Start
2006-06-15
Budget End
2007-05-31
Support Year
1
Fiscal Year
2006
Total Cost
$364,945
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Faherty, Christina S; Wu, Tao; Morris, Carolyn R et al. (2016) The synthesis of OspD3 (ShET2) in Shigella flexneri is independent of OspC1. Gut Microbes 7:486-502
Morris, Carolyn R; Grassel, Christen L; Redman, Julia C et al. (2013) Characterization of intracellular growth regulator icgR by utilizing transcriptomics to identify mediators of pathogenesis in Shigella flexneri. Infect Immun 81:3068-76
Barry, Eileen M; Pasetti, Marcela F; Sztein, Marcelo B et al. (2013) Progress and pitfalls in Shigella vaccine research. Nat Rev Gastroenterol Hepatol 10:245-55
Faherty, Christina S; Faherty, Christina; Harper, Jill M et al. (2012) Chromosomal and plasmid-encoded factors of Shigella flexneri induce secretogenic activity ex vivo. PLoS One 7:e49980
Faherty, Christina S; Redman, Julia C; Rasko, David A et al. (2012) Shigella flexneri effectors OspE1 and OspE2 mediate induced adherence to the colonic epithelium following bile salts exposure. Mol Microbiol 85:107-21
Wu, Tao; Grassel, Christen; Levine, Myron M et al. (2011) Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit. Infect Immun 79:4912-22
Farfan, Mauricio J; Toro, Cecilia S; Barry, Eileen M et al. (2011) Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells. FEMS Immunol Med Microbiol 61:332-9
Baker, K K; Levine, M M; Morison, J et al. (2009) CfaE tip mutations in enterotoxigenic Escherichia coli CFA/I fimbriae define critical human intestinal binding sites. Cell Microbiol 11:742-54
Levine, Myron M; Kotloff, Karen L; Barry, Eileen M et al. (2007) Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat Rev Microbiol 5:540-53